Acclimating Practice to the Current Treatment Landscape in FL: Emerging Evidence and Recent Results

Join us online for this live 1.5-hour, CME-certified Webinar to gain expert guidance on optimal management of relapsed/refractory follicular lymphoma. Experts will review the latest clinical data, including insights from the ASH 2022 annual meeting, along with discussing patient cases and answering audience questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


• Welcome and Introduction
• Overview of Relapsed/Refractory FL and Unmet Needs – Laurie Sehn, MD
• Epigenetic Modifiers and PI3K Inhibitors – Ian Flinn, MD, PhD
• Bispecific Antibodies – Laurie Sehn, MD
• CAR T-Cell Therapy – Ian Flinn, MD, PhD
• Final Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Vancouver, Canada

Ian W. Flinn, MD, PhD

Director, Lymphoma Research 
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of HCPs treating patients with relapsed/refractory follicular lymphoma by leveraging recent and emerging data that must be considered in treatment decisions.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with FL, including hematologists/oncologists, advanced care practitioners, pharmacists, and nurses.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Incorporate safety and efficacy data on novel and emerging therapies into management plans for patients with relapsed/refractory follicular lymphoma
  • Plan the optimal sequence of PI3K inhibitors, epigenetic modifiers, CAR T-cell therapy, and antibodies for patients with relapsed/refractory follicular lymphoma based on available evidence, as well as guideline and expert recommendations
  • Manage adverse events associated with novel treatment regimens in relapsed/refractory follicular lymphoma
  • Identify patients with relapsed/refractory follicular lymphoma who are eligible for enrollment on a clinical trial


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.